Literature DB >> 23175121

The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.

Azra Raza1, Naomi Galili.   

Abstract

Myelodysplastic syndromes (MDS) are malignant clonal disorders of haematopoietic stem cells and their microenvironment, affecting older individuals (median age ∼70 years). Unique features that are associated with MDS - but which are not necessarily present in every patient with MDS - include excessive apoptosis in maturing clonal cells, a pro-inflammatory bone marrow microenvironment, specific chromosomal abnormalities, abnormal ribosomal protein biogenesis, the presence of uniparental disomy, and mutations affecting genes involved in proliferation, methylation and epigenetic modifications. Although emerging insights establish an association between molecular abnormalities and the phenotypic heterogeneity of MDS, their origin and progression remain enigmatic.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23175121     DOI: 10.1038/nrc3321

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  106 in total

Review 1.  Signaling pathways that regulate life and cell death: evolution of apoptosis in the context of self-defense.

Authors:  Cristina Muñoz-Pinedo
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

2.  Diagnostic microRNAs in myelodysplastic syndrome.

Authors:  Begum Erdogan; Crystal Facey; Julianne Qualtieri; Jason Tedesco; Elizabeth Rinker; R Benjamin Isett; John Tobias; Donald A Baldwin; James E Thompson; Martin Carroll; Annette S Kim
Journal:  Exp Hematol       Date:  2011-06-15       Impact factor: 3.084

3.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor.

Authors:  Yang-Sook Cho; Eun-Joo Kim; Ui-Hyun Park; Hong-Sig Sin; Soo-Jong Um
Journal:  J Biol Chem       Date:  2006-04-10       Impact factor: 5.157

5.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

6.  Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.

Authors:  Christina Evers; Manfred Beier; Anne Poelitz; Barbara Hildebrandt; Kati Servan; Matthias Drechsler; Ulrich Germing; Hans-Dieter Royer; Brigitte Royer-Pokora
Journal:  Genes Chromosomes Cancer       Date:  2007-12       Impact factor: 5.006

7.  Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes.

Authors:  S D Mundle; P Venugopal; J D Cartlidge; D V Pandav; L Broady-Robinson; S Gezer; E L Robin; S R Rifkin; M Klein; D E Alston; B M Hernandez; D Rosi; S Alvi; V T Shetty; S A Gregory; A Raza
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

8.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

Authors:  Ramiro Garzon; Stefano Volinia; Chang-Gong Liu; Cecilia Fernandez-Cymering; Tiziana Palumbo; Flavia Pichiorri; Muller Fabbri; Kevin Coombes; Hansjuerg Alder; Tatsuya Nakamura; Neal Flomenberg; Guido Marcucci; George A Calin; Steven M Kornblau; Hagop Kantarjian; Clara D Bloomfield; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

9.  DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia.

Authors:  M Ewalt; N G Galili; M Mumtaz; M Churchill; S Rivera; F Borot; A Raza; S Mukherjee
Journal:  Blood Cancer J       Date:  2011-03-11       Impact factor: 11.037

10.  An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.

Authors:  Benjamin L Ebert; Naomi Galili; Pablo Tamayo; Jocelyn Bosco; Raymond Mak; Jennifer Pretz; Shyam Tanguturi; Christine Ladd-Acosta; Richard Stone; Todd R Golub; Azra Raza
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

View more
  57 in total

Review 1.  Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).

Authors:  Ehab Atallah; Kathryn Bylow; Jesse Troy; Wael Saber
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

2.  Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.

Authors:  S Jilg; V Reidel; C Müller-Thomas; J König; J Schauwecker; U Höckendorf; C Huberle; O Gorka; B Schmidt; R Burgkart; J Ruland; H-J Kolb; C Peschel; R A J Oostendorp; K S Götze; P J Jost
Journal:  Leukemia       Date:  2015-07-08       Impact factor: 11.528

3.  Longitudinal Analysis of DNA Methylation in CD34+ Hematopoietic Progenitors in Myelodysplastic Syndrome.

Authors:  Yan-Fung Wong; Chris N Micklem; Masataka Taguchi; Hidehiro Itonaga; Yasushi Sawayama; Daisuke Imanishi; Shinichi Nishikawa; Yasushi Miyazaki; Lars Martin Jakt
Journal:  Stem Cells Transl Med       Date:  2014-08-13       Impact factor: 6.940

4.  Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes.

Authors:  Lingxu Jiang; Lu Wang; Chuying Shen; Shuanghong Zhu; Wei Lang; Yingwan Luo; Hua Zhang; Wenli Yang; Yueyuan Han; Liya Ma; Yanling Ren; Xinping Zhou; Chen Mei; Li Ye; Weilai Xu; Haiyang Yang; Chenxi Lu; Jie Jin; Hongyan Tong
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 5.  Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Mohamed A Kharfan-Dabaja; Rami S Komrokji
Journal:  Curr Opin Hematol       Date:  2014-03       Impact factor: 3.284

6.  Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?

Authors:  Amer M Zeidan; Thomas Prebet; Ehab Saad Aldin; Steven David Gore
Journal:  Expert Rev Hematol       Date:  2014-02-24       Impact factor: 2.929

7.  Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?

Authors:  Amer M Zeidan; Steven D Gore
Journal:  Expert Rev Hematol       Date:  2013-10-04       Impact factor: 2.929

8.  Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes.

Authors:  Abdullah Mahmood Ali; Yumin Huang; Ronald Feitosa Pinheiro; Fumin Xue; Jingping Hu; Nicholas Iverson; Daniela Hoehn; Diego Coutinho; Jehanzeb Kayani; Brian Chernak; Joseph Lane; Christopher Hillyer; Naomi Galili; Joseph Jurcic; Narla Mohandas; Xiuli An; Azra Raza
Journal:  Blood Adv       Date:  2018-06-26

9.  PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia.

Authors:  A A Guirguis; C I Slape; L M Failla; J Saw; C S Tremblay; D R Powell; F Rossello; A Wei; A Strasser; D J Curtis
Journal:  Cell Death Differ       Date:  2016-01-08       Impact factor: 15.828

Review 10.  Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD).

Authors:  Toshio Kitamura; Naoko Watanabe-Okochi; Yutaka Enomoto; Fumio Nakahara; Toshihiko Oki; Yukiko Komeno; Naoko Kato; Noriko Doki; Tomoyuki Uchida; Yuki Kagiyama; Katsuhiro Togami; Kimihito C Kawabata; Koutarou Nishimura; Yasutaka Hayashi; Reina Nagase; Makoto Saika; Tsuyoshi Fukushima; Shuhei Asada; Takeshi Fujino; Yuto Izawa; Sayuri Horikawa; Tomofusa Fukuyama; Yosuke Tanaka; Ryoichi Ono; Susumu Goyama; Tetsuya Nosaka; Jiro Kitaura; Daichi Inoue
Journal:  J Biochem       Date:  2015-11-20       Impact factor: 3.387

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.